Ziopharm Oncology (NASDAQ:ZIOP) was downgraded by Zacks Investment Research from a “hold” rating to a “sell” rating in a research note issued on Wednesday.
According to Zacks, “ZIOPHARM Oncology, Inc. is a biopharmaceutical company engaged in the development and commercialization of a diverse, risk-sensitive portfolio of in-licensed cancer drugs to address unmet medical needs. The Company applies new insights from molecular and cancer biology to understand the efficacy and safety limitations of approved and developmental cancer therapies and identifies proprietary and related molecules for better patient treatment. “
Other equities research analysts have also issued reports about the stock. BidaskClub upgraded shares of Ziopharm Oncology from a “strong sell” rating to a “sell” rating in a research report on Wednesday, April 4th. ValuEngine upgraded shares of Ziopharm Oncology from a “strong sell” rating to a “sell” rating in a research report on Wednesday, May 2nd. Finally, HC Wainwright set a $10.00 price objective on shares of Ziopharm Oncology and gave the stock a “buy” rating in a research report on Monday, March 5th. Two research analysts have rated the stock with a sell rating, two have assigned a hold rating and one has issued a buy rating to the company’s stock. The company currently has an average rating of “Hold” and a consensus price target of $5.25.
Ziopharm Oncology opened at $4.45 on Wednesday, Marketbeat reports. Ziopharm Oncology has a fifty-two week low of $4.42 and a fifty-two week high of $4.52. The firm has a market cap of $644.78 million, a PE ratio of -8.40 and a beta of 1.74.
Ziopharm Oncology (NASDAQ:ZIOP) last released its quarterly earnings data on Thursday, May 10th. The biotechnology company reported ($0.15) EPS for the quarter, missing the consensus estimate of ($0.13) by ($0.02). The company had revenue of $0.15 million for the quarter, compared to analyst estimates of $1.55 million. research analysts predict that Ziopharm Oncology will post -0.52 earnings per share for the current year.
Several institutional investors have recently added to or reduced their stakes in ZIOP. Schwab Charles Investment Management Inc. boosted its position in shares of Ziopharm Oncology by 4.2% in the 4th quarter. Schwab Charles Investment Management Inc. now owns 644,642 shares of the biotechnology company’s stock worth $2,669,000 after buying an additional 26,053 shares in the last quarter. Teacher Retirement System of Texas boosted its position in shares of Ziopharm Oncology by 302.7% in the 4th quarter. Teacher Retirement System of Texas now owns 42,517 shares of the biotechnology company’s stock worth $176,000 after buying an additional 31,958 shares in the last quarter. BlackRock Inc. boosted its position in shares of Ziopharm Oncology by 3.4% in the 4th quarter. BlackRock Inc. now owns 8,499,209 shares of the biotechnology company’s stock worth $35,187,000 after buying an additional 280,003 shares in the last quarter. Virtu Financial LLC boosted its position in shares of Ziopharm Oncology by 877.6% in the 4th quarter. Virtu Financial LLC now owns 98,638 shares of the biotechnology company’s stock worth $408,000 after buying an additional 88,548 shares in the last quarter. Finally, Virtus Fund Advisers LLC purchased a new stake in shares of Ziopharm Oncology in the 4th quarter worth about $338,000. Institutional investors and hedge funds own 40.12% of the company’s stock.
Ziopharm Oncology Company Profile
ZIOPHARM Oncology, Inc, a biotechnology company, focuses on acquiring, developing, and commercializing a portfolio of immuno-oncology therapies for treating heterogenous solid tumors and unknown antigens. The company develops two immuno-oncology platform technologies, including Controlled IL-12, which delivers interleukin 12 or IL-12, a master regular of the immune system, in a controlled and safe manner to focus the patient's immune system to cancer; and Sleeping Beauty (SB), which is based on the genetic engineering of T-cells using the (SB) system to rapidly reprogram T-cells outside of the body for infusion.
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Ziopharm Oncology Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Ziopharm Oncology and related companies with MarketBeat.com's FREE daily email newsletter.